The addition of acalabrutinib to standard-of-care chemoimmunotherapy significantly extended PFS compared with standard therapy alone in a randomized study, according to press release the agent’s ...
The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for certain adults ...
Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.
The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.
The US Food and Drug Administration (FDA) has approved a lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.)-based ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback